AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12833248 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic muscle-strengthening exercise
Number of subjects: 132
Study 12833248 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric muscle-strengthening exercise
Number of subjects: 132
Study 12833248 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 132
Study 10796061 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) formulation of indapamide (2.5 mg)
Number of subjects: 12
Study 10796061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Release (SR) formulation of indapamide (1.5 mg)
Number of subjects: 12
Study 10796061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Release (SR) formulation of indapamide (1.5 mg) after repeated administration
Number of subjects: 12
Study 10796061 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) formulation of indapamide (2.5 mg) after repeated administration
Number of subjects: 12
Study 8891006 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% urea ointment
Number of subjects: 10
Study 8891006 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 10
Study 8891006 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 10
Study 1795202 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (ACE inhibitor)
Number of subjects: 0
Study 1795202 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting calcium antagonists
Number of subjects: 0
Study 1795202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6337580 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 103
Study 6337580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 31403596 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Over Matter: Healthy Bowels, Healthy Bladder (treatment group)
Number of subjects: 121
Study 31403596 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 121
Study 27540899 — intervention group
Group type: EXPERIMENTAL
Intervention: PA+SMS group (text messaging cues before PA sessions)
Number of subjects: 49
Study 27540899 — intervention group
Group type: COMPARATOR
Intervention: PA group (28-week supervised PA program without SMS)
Number of subjects: 49
Study 27540899 — intervention group
Group type: EXPERIMENTAL
Intervention: PA+SMS group
Number of subjects: 49
Study 25910838 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturized cardiopulmonary bypass (MCPB)
Number of subjects: 68
Study 25910838 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiopulmonary bypass (CCPB)
Number of subjects: 68
Study 25910838 — intervention group
Group type: EXPERIMENTAL
Intervention: MCPB
Number of subjects: 68
Study 25910838 — intervention group
Group type: COMPARATOR
Intervention: CCPB
Number of subjects: 68
Study 21876219 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory screw
Number of subjects: 32
Study 21876219 — intervention group
Group type: COMPARATOR
Intervention: Hyrax screw
Number of subjects: 32
Study 22552194 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive oesophagectomy
Number of subjects: 115
Study 22552194 — intervention group
Group type: COMPARATOR
Intervention: Open oesophagectomy
Number of subjects: 115
Study 19222610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10/20 mg
Number of subjects: 618
Study 19222610 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 618
Study 17710289 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice A (523 microgF/g)
Number of subjects: 33
Study 17710289 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice B (1,062 microgF/g)
Number of subjects: 33
Study 17710289 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice C (1,373 microgF/g)
Number of subjects: 33
Study 15156389 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-shape compression anastomosis clip (CAC)
Number of subjects: 10
Study 15156389 — intervention group
Group type: COMPARATOR
Intervention: Stapler
Number of subjects: 10
Study 12577455 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral administration of 30 g of alanyl‐glutamine dipeptide (Dipeptiven, Fresenius‐Kabi) from day +1 to day +14 or to discharge from hospital
Number of subjects: 40
Study 12577455 — intervention group
Group type: COMPARATOR
Intervention: Isolated control group receiving isonitrogenous glutamine‐free amino acid solution from day +1 to day +14 or to discharge from hospital
Number of subjects: 40
Study 12577455 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition in dose of 26.5 kcal/kg and 1 g of amino acid/kg given to patients who did not reach adequate oral intake for 5 days
Number of subjects: 40
Study 10199111 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) titrated to a dose of 0.7 mg/kg
Number of subjects: 91
Study 10199111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 8914492 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight training
Number of subjects: 142
Study 8914492 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 142
Study 1830259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin delivery (15 units of insulin in 1% sodium glycocholate)
Number of subjects: 6
Study 1830259 — intervention group
Group type: COMPARATOR
Intervention: Glycocholate alone (placebo)
Number of subjects: 6
Study 6858980 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppository group
Number of subjects: 84
Study 6858980 — intervention group
Group type: COMPARATOR
Intervention: Nonsuppository group
Number of subjects: 84
Study 31471309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 413
Study 31471309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 413
Study 31471309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 31471309 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CXCL10
Number of subjects: 413
Study 29795452 — intervention group
Group type: EXPERIMENTAL
Intervention: Video during direct laryngoscopy (VDL)
Number of subjects: 48
Study 29795452 — intervention group
Group type: COMPARATOR
Intervention: Traditional direct laryngoscopy (TDL)
Number of subjects: 48
Study 26965165 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week, group-based, behaviour-change programme with weekly 90-min sessions about healthy eating and physical activity
Number of subjects: 64
Study 26965165 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 64
Study 24633809 — intervention group
Group type: EXPERIMENTAL
Intervention: MNRP1685A (7.5, 15, 24, and 36 mg/kg) with bevacizumab 15 mg/kg every 3 weeks (Arm A)
Number of subjects: 24
Study 24633809 — intervention group
Group type: EXPERIMENTAL
Intervention: MNRP1685A (12 and 16 mg/kg) with bevacizumab 10 mg/kg every 2 weeks and paclitaxel 90 mg/m(2) weekly (Arm B)
Number of subjects: 24
Study 24633809 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MNRP1685A with bevacizumab
Number of subjects: 24
Study 24399119 — intervention group
Group type: EXPERIMENTAL
Intervention: IDIProst® Gold (one capsule q24 h) for 3 months
Number of subjects: 129
Study 24399119 — intervention group
Group type: COMPARATOR
Intervention: Serenoa repens 320 mg (one capsule q24h) for 3 months
Number of subjects: 129
Study 20500277 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered home visits combined with telephone intervention
Number of subjects: 116
Study 20500277 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 116
Study 17953792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (24 mg day(-1))
Number of subjects: 105
Study 17953792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone (5 g day(-1))
Number of subjects: 105
Study 17953792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 16904312 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy with vincristine and actinomycin D for 6 weeks
Number of subjects: 205
Study 16904312 — intervention group
Group type: COMPARATOR
Intervention: Immediate nephrectomy
Number of subjects: 205
Study 12829678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidimensional (BD) measurements
Number of subjects: 33
Study 12829678 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidimensional (UD) measurements
Number of subjects: 33
Study 12829678 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO criteria for tumor progression
Number of subjects: 33
Study 12829678 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO criteria for tumor response
Number of subjects: 33
Study 12829678 — intervention group
Group type: EXPERIMENTAL
Intervention: RECIST criteria for tumor progression
Number of subjects: 33
Study 12829678 — intervention group
Group type: EXPERIMENTAL
Intervention: RECIST criteria for tumor response
Number of subjects: 33
Study 10819345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonavalent protein conjugate pneumococcal vaccine (PnCV)
Number of subjects: 207
Study 10819345 — intervention group
Group type: COMPARATOR
Intervention: Inactivated polio vaccine (IPV)
Number of subjects: 207
Study 9019122 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured diary keeping
Number of subjects: 0
Study 9019122 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured recall
Number of subjects: 0
Study 9019122 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured diary keeping and structured recall
Number of subjects: 0
Study 1394200 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant interleukin 2
Number of subjects: 25
Study 1394200 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 3924065 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (750 mg/day)
Number of subjects: 20
Study 3924065 — intervention group
Group type: COMPARATOR
Intervention: Clofibate (2 g/day)
Number of subjects: 20
Study 30882846 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone therapy
Number of subjects: 0
Study 29720113 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-driven antiemetic therapy
Number of subjects: 185
Study 29720113 — intervention group
Group type: COMPARATOR
Intervention: Single agent antiemetic therapy with haloperidol
Number of subjects: 185
Study 29720113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 185
Study 26746868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) administered via four monthly intravitreal injections and then as needed per protocol
Number of subjects: 117
Study 25155371 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin); administered every 4 weeks, pro re nata.
Number of subjects: 61
Study 25155371 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone implant (Ozurdex); administered every 16 weeks, pro re nata.
Number of subjects: 61
Study 25155371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Bevacizumab and Dexamethasone implant)
Number of subjects: 61
Study 22368041 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal esophageal pH capsule
Number of subjects: 22
Study 20415839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBO(2)T) administered in a course of 20 treatments at pressures between 1.75ATA and 2.5ATA daily for 60-120 min over 4 weeks
Number of subjects: 0
Study 20415839 — intervention group
Group type: COMPARATOR
Intervention: Placebo regimen
Number of subjects: 0
Study 18541979 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil (5 mg, n=11 or 10 mg, n=1)
Number of subjects: 20
Study 18541979 — intervention group
Group type: COMPARATOR
Intervention: placebo (n=8)
Number of subjects: 20
Study 16358411 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuwei Dihuang pill (LWDH)
Number of subjects: 64
Study 16358411 — intervention group
Group type: EXPERIMENTAL
Intervention: LWDH
Number of subjects: 64
Study 16358411 — intervention group
Group type: COMPARATOR
Intervention: Control group (Conventional treatment with prednisone and CTX)
Number of subjects: 64
Study 12869000 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made screw implants with plaque control terminated at one implant and continued at the other implant after one month of abutment connection.
Number of subjects: 12
Study 12869000 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made screw implants with varying periods of plaque accumulation (7, 21, or 90 days).
Number of subjects: 12
Study 10370915 — intervention group
Group type: EXPERIMENTAL
Intervention: Static foot posture measures (subtalar neutral position, forefoot/rearfoot position, ankle joint dorsiflexion, tibial angle in standing, calcaneal angle in standing)
Number of subjects: 74
Study 10370915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic foot posture measures (rearfoot supination and pronation) during the stance phase of gait
Number of subjects: 74
Study 10370915 — intervention group
Group type: COMPARATOR
Intervention: Comparison of foot postures between injured and uninjured players
Number of subjects: 74
Study 10370915 — intervention group
Group type: COMPARATOR
Intervention: Foot postures comparison based on player position
Number of subjects: 74
Study 8654639 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized methods of pituitary desensitization, ovarian stimulation, and IVF‐ET with a maximum of three embryos transferred
Number of subjects: 561
Study 8654639 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized methods of pituitary desensitization, ovarian stimulation, and IVF‐ET with four or more embryos transferred
Number of subjects: 561
Study 8654639 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized methods of pituitary desensitization, ovarian stimulation, and IVF‐ET
Number of subjects: 561
Study 7970453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose RU 486 (5 mg alternate days for four doses, beginning 3 days after the urinary LH surge)
Number of subjects: 7
Study 7970453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3677558 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary isocapnic hyperventilation during exercise
Number of subjects: 9
Study 3677558 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing during exercise
Number of subjects: 9
Study 3677558 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary isocapnic hyperventilation
Number of subjects: 9
Study 27676117 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniperc
Number of subjects: 150
Study 27676117 — intervention group
Group type: COMPARATOR
Intervention: SWL
Number of subjects: 150
Study 30538436 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle risk reduction intervention including sessions with a dietitian, online brain training, and sessions with an exercise physiologist.
Number of subjects: 0
Study 30538436 — intervention group
Group type: COMPARATOR
Intervention: Active control group receiving four online educational modules: dementia literacy and lifestyle risk, Mediterranean diet, cognitive engagement, and physical activity.
Number of subjects: 0
Study 30538436 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle risk reduction intervention
Number of subjects: 0
Study 30538436 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study 26915630 — intervention group
Group type: COMPARATOR
Intervention: Conventional Risk Score (CRS)
Number of subjects: 203
Study 26915630 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Risk Score (GRS)
Number of subjects: 203
Study 26915630 — intervention group
Group type: EXPERIMENTAL
Intervention: High GRS
Number of subjects: 203
Study 26915630 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GRS
Number of subjects: 203
Study 26915630 — intervention group
Group type: EXPERIMENTAL
Intervention: (+GRS) group
Number of subjects: 203
Study 27100654 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL Master 500
Number of subjects: 40
Study 27100654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam HR
Number of subjects: 40
Study 27100654 — intervention group
Group type: EXPERIMENTAL
Intervention: LenStar 900
Number of subjects: 40
Study 27100654 — intervention group
Group type: COMPARATOR
Intervention: IOL Master 500, LenStar 900, Pentacam HR
Number of subjects: 40
Study 23579624 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensives (H)
Number of subjects: 45
Study 21913547 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3.5mg/kg
Number of subjects: 60
Study 21913547 — intervention group
Group type: COMPARATOR
Intervention: Halothane 3%
Number of subjects: 60
Study 19803570 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG)
Number of subjects: 758
Study 19803570 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 758
Study 17100775 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli endotoxin (LPS) 20 IU/kg
Number of subjects: 6
Study 17100775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 17100775 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS
Number of subjects: 6
Study 17100775 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1, IL-6, TNF-alpha
Number of subjects: 6
Study 17100775 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10
Number of subjects: 6
Study 14980101 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-IFN alpha-2a (Pegasys)
Number of subjects: 202
Study 14980101 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha-2a (Roferon-A)
Number of subjects: 202
Study 14980101 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype 1
Number of subjects: 202
Study 14980101 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype non-1
Number of subjects: 202
Study 11317155 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (300 mg)
Number of subjects: 9
Study 11317155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10897972 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg daily
Number of subjects: 1500
Study 10897972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 7640038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive weekly regimen of cisplatin (70-85 mg/m2)
Number of subjects: 107
Study 7640038 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly combination chemotherapy with cisplatin (75 mg/m2)
Number of subjects: 107
Study 7640038 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly regimen with cisplatin (20 mg/m2 for 5 days)
Number of subjects: 107
Study 2502737 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 30
Study 2502737 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 30
Study 1252671 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin D2 (10 ng)
Number of subjects: 0
Study 1252671 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin D2 (10, 20 and 50 ng)
Number of subjects: 0
Study 1252671 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin D2 (100 ng and above)
Number of subjects: 0
Study 1252671 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2
Number of subjects: 0
Study 1252671 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin D1
Number of subjects: 0
Study 1252671 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E1
Number of subjects: 0
Study 31305282 — intervention group
Group type: EXPERIMENTAL
Intervention: BREASTChoice
Number of subjects: 120
Study 31305282 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 120
Study 31395425 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism Adaptation (PA) combined with continuous theta‐burst transcranial magnetic stimulation (cTBS) over the left intact parietal cortex
Number of subjects: 14
Study 31395425 — intervention group
Group type: COMPARATOR
Intervention: Prism Adaptation (PA) alone
Number of subjects: 14
Study 28985813 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 suture + CXL
Number of subjects: 20
Study 28985813 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sutures + CXL
Number of subjects: 20
Study 28985813 — intervention group
Group type: COMPARATOR
Intervention: 3 sutures
Number of subjects: 20
Study 28531469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe therapy
Number of subjects: 34
Study 28531469 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil supplementation
Number of subjects: 34
Study 28531469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe and flaxseed oil supplementation
Number of subjects: 34
Study 28531469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 23437959 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg/day
Number of subjects: 296
Study 23437959 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg/day
Number of subjects: 296
Study 23437959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 20530082 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health education delivered by lay health workers
Number of subjects: 4023
Study 20530082 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4023
Study 19055335 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (once a week for 10 weeks, in addition to conservative treatment with medication)
Number of subjects: 30
Study 19055335 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment with medication only (control group)
Number of subjects: 30
Study 19055335 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 30
Study 16899485 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous treprostinil
Number of subjects: 860
Study 16899485 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous treprostinil monotherapy
Number of subjects: 860
Study 16899485 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous treprostinil in idiopathic pulmonary arterial hypertension (IPAH) patients
Number of subjects: 860
Study 16899485 — intervention group
Group type: COMPARATOR
Intervention: Predicted survival
Number of subjects: 860